as 01-17-2025 4:00pm EST
Stocks
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company leading the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
Founded: | 2021 | Country: | United States |
Employees: | N/A | City: | MIAMI |
Market Cap: | 154.1M | IPO Year: | 2024 |
Target Price: | N/A | AVG Volume (30 days): | 225.7K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.79 | EPS Growth: | N/A |
52 Week Low/High: | $3.11 - $20.72 | Next Earning Date: | 02-12-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
TELO Breaking Stock News: Dive into TELO Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Zacks Small Cap Research
6 days ago
ACCESSWIRE
12 days ago
Zacks Small Cap Research
12 days ago
ACCESSWIRE
a month ago
Benzinga
a month ago
ACCESSWIRE
a month ago
ACCESSWIRE
2 months ago
The information presented on this page, "TELO TELOMIR PHARMACEUTICALS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.